United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 7,886 shares of the firm’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $572.69, for a total value of $4,516,233.34. Following the transaction, the chief executive officer owned 326,057 shares of the company’s stock, valued at approximately $186,729,583.33. The trade was a 2.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
United Therapeutics Trading Up 1.1%
Shares of NASDAQ:UTHR traded up $6.15 during mid-day trading on Tuesday, reaching $588.61. The stock had a trading volume of 433,109 shares, compared to its average volume of 556,544. The company has a market cap of $25.25 billion, a P/E ratio of 22.21, a price-to-earnings-growth ratio of 4.41 and a beta of 0.49. United Therapeutics Corporation has a 1 year low of $449.58 and a 1 year high of $614.23. The business’s 50 day moving average price is $535.33 and its 200 day moving average price is $533.99.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The firm had revenue of $832.50 million for the quarter, compared to analysts’ expectations of $781.14 million. During the same quarter in the prior year, the business earned $7.16 EPS. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. Analysts predict that United Therapeutics Corporation will post 24.77 earnings per share for the current fiscal year.
United Therapeutics declared that its board has approved a share repurchase plan on Thursday, October 22nd that permits the company to repurchase $2 billion in shares. This buyback authorization permits the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its shares are undervalued.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in shares of United Therapeutics in the second quarter worth approximately $2,868,735,000. Janus Henderson Group PLC boosted its holdings in United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after acquiring an additional 70,829 shares during the period. Jupiter Topco LLC purchased a new position in United Therapeutics during the 2nd quarter valued at $450,140,000. Bank of New York Mellon Corp bought a new position in United Therapeutics in the 2nd quarter valued at $159,522,000. Finally, Caisse de depot et placement du Quebec bought a new position in United Therapeutics in the 2nd quarter valued at $154,304,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.
Analyst Upgrades and Downgrades
UTHR has been the topic of several research reports. HC Wainwright started coverage on shares of United Therapeutics in a research report on Monday. They issued a “buy” rating and a $660.00 price target on the stock. Raymond James Financial set a $720.00 price objective on United Therapeutics in a research report on Wednesday, November 4th. Wells Fargo & Company raised their price objective on United Therapeutics from $700.00 to $703.00 and gave the company an “overweight” rating in a research note on Thursday, November 5th. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $850.00 price target on shares of United Therapeutics in a research report on Monday, October 26th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $676.40.
Get Our Latest Analysis on UTHR
United Therapeutics Company Profile
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Featured Stories
- Five stocks we like better than United Therapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
